Pancreatic Cancer | Topics

Study results suggested that maintenance olaparib (Lynparza) is potentially cost-effective compared with placebo for patients with metastatic pancreatic cancer and a germline BRCA mutation.

The latest installment of “Oncology Peer Review On-The-Go” dissects original research published in the journal ONCOLOGY regarding potential barriers to clinical trial enrollment for patients with pancreatic cancer.

This 20-year analysis suggested that weight loss surgery significantly decreases the risk of developing pancreatic cancer in individuals who are obese with diabetes.